Sarepta competitor files with FDA for Duchenne drug

Sarepta competitor files with FDA for Duchenne drug

Submitted by admin on October 2, 2019 - 12:12pm
Source: 
Seeking Alpha
News Tags: 
Sarepta Therapeutics
NS Pharma
golodirsen
FDA
Duchenne Muscular Dystrophy
Headline: 
Sarepta competitor files with FDA for Duchenne drug
snippet: 

Sarepta Therapeutics (NASDAQ:SRPT) -3% pre-market after Japanese drugmaker NS Pharma said it filed with the U.S. Food and Drug Administration to seek approval for its new drug to treat Duchenne muscular dystrophy.

Do Not Allow Advertisers to Use My Personal information